We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Prelude Therapeutics Inc (PRLD) USD0.0001

Sell:$3.71 Buy:$3.75 Change: $0.36 (8.80%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.36 (8.80%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.36 (8.80%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Contact details

175 Innovation Boulevard
United States
+1 (302) 4671280

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$224.66 million
Shares in issue:
42.08 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Jane Huang
    President, Chief Medical Officer
  • Krishna Vaddi
    Chief Executive Officer, Founder, Director
  • Bryant Lim
    Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary
  • Andrew Combs
    Executive Vice President, Head of Chemistry
  • Robert Doody
    Senior Vice President of Investor Relations
  • Peggy Scherle
    Chief Scientific Officer
  • Sean Brusky
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.